Fixed-dose combination: beware of its limitations

Neelesh Gupta, Mohammed Elkhazendar, Rajeev Gupta

Full Text:

PDF HTML

References


Ryder REJ, Abdul-Ghani MA, DeFronzo RA. Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020. Br J Diabetes. 2020;20(2):85-8. https://doi.org/10.15277/bjd.2020.276

Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program. Circulation. 2018;138(5):458-68. https://doi.org/10.1161/circulationaha.118.034222

Inzucchi SE, Fitchett D, Jurišić-Eržen D, et al. Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy? Diabetes, Obesity and Metabolism. 2020;22(4):631-9. https://doi.org/10.1111/dom.13938

Han Y, Xie H, Liu Y, et al. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovascular Diabetology. 2019;18(1):96. 10.1186/s12933-019-0900-7

Crowley MJ, Gokhale M, Pate V, et al. Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. Diabetes Obes Metab. 2019;21(4):854-65. https://10.1111/dom.13589




DOI: https://doi.org/10.15277/bjd.2021.289

Refbacks

  • There are currently no refbacks.


The Journal of the Association of British Clinical Diabetologists